HAMILTON, ON, June 12, 2025 – CPDC, a global leader in the development and commercialization of radiopharmaceuticals, today announced a $650,000 seed investment in RadioSyn Ltd., a Hamilton-based startup company developing a miniaturized automated radiopharmaceutical synthesis device. The shielded synthesizer uses disposable microfluidic chips to perform end-to-end chemical and radiochemical reactions to synthesize radiopharmaceuticals at the bench.
“Our device offers cost-effective, on-demand delivery of radiopharmaceuticals, making it ideal for meeting the growing demand for personalized and precision medicine,” said Saman Sadeghi, RadioSyn co-founder and CEO, and Associate Professor of Chemistry and Chemical Biology at McMaster University.
“CPDC is actively pursuing direct investments in early-stage radiopharmaceutical companies focused on therapeutics, diagnostics, and enabling technologies,” said Owen Roberts, CEO of CPDC. “There is an urgent need for innovation in radiopharmaceutical production, and RadioSyn is developing a compelling solution that simplifies and miniaturizes the process while delivering reliable, high-quality results. With our investment, RadioSyn is ready to demonstrate proof-of-concept within the next year, paving the way for commercialization.”
About CPDC
CPDC is a not-for-profit advancing nuclear medicine in Canada and beyond through strategic investments, expert guidance and innovative radiopharmaceutical development to benefit patients globally. In the past 17 years, CPDC has created four Canadian commercial entities that have accelerated the availability of radiopharmaceuticals to the Canadian and global medical community. CPDC will continue to identify and advance critical radiopharmaceuticals to meet the needs of patients and physicians through our collaborations with partners including industry, academia, and government. For more information on CPDC, visit www.cpdc.ca and follow on LinkedIn.
About RadioSyn
RadioSyn is a McMaster University startup that is designing and manufacturing a miniaturized automated radiopharmaceutical synthesis platform. They deliver a shielded, state-of-the-art synthesizer that eliminates traditional production barriers and complexity. Their automated synthesis technology platform addresses critical limitations in conventional diagnostic and therapeutic workflows by standardizing and streamlining radioimmunoconjugate and radiopharmaceutical manufacturing. For more information, visit www.radiosyn.com